Adaptimmune Q1 2021 Earnings Report
Key Takeaways
Adaptimmune reported first quarter financial results, with a revenue of $0.4 million and a net loss of $37.8 million. The company's cash and cash equivalents totaled $32.4 million, and total liquidity reached $317.9 million. Financial guidance confirmed funding into early 2023.
Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO
First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT
Enrollment momentum in SURPASS and ADP-A2AFP clinical trials increased in Q1
Astellas nominates second target as part of allogeneic co-development and co-commercialization agreement
Adaptimmune
Adaptimmune
Forward Guidance
The Company believes that its existing cash, cash equivalents and marketable securities will fund the Company’s current operations into early 2023.